Overview

Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers

Status:
Completed

Trial end date:
2018-03-29

Target enrollment:

Participant gender:

Summary

The purpose of this trial to compare the pharmacokinetic characteristics of YNP-1807(Pregabalin 330mg) and Lyrica capsule(Pregabalin 150mg). YNP-1807 is made by Yungjin Pharm. Primary endpoints are AUClast and Cmax and secondary endpoints are AUCinf, Tmax, t1/2, Vd/f, CL/f.

Phase:

Phase 1

Details

Lead Sponsor:

Yungjin Pharm. Co., Ltd.

Treatments:

Pregabalin